Matrix Partners Leads $53M Series B Round In Chinese Biopharma Firm Adlai Nortye
July 6, 2018 — 10:24 CST
This Data Is Locked!
This area is available only to Subscribers.
Hangzhou-based biopharmaceutical company Adlai Nortye Biopharma announced that it has raised a US$53 million series B round from Matrix Partners China and other investors. YuanMing... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
